Cookies

We use cookies to ensure that we give you the best experience on our website. If you click accept my preferences we'll assume that you are happy to receive all cookies on our website. Visit our Cookie Policy and our Privacy Policy for more information about managing your cookies.

Sign In

Confirm

Eight new medicines recommended for approval

British Journal of Family Medicine, July, 2013

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Giotrif for the treatment of lung cancer. The CHMP also recommended that Incresync, Vipdomet and Vipidia should be granted marketing authorisations for the treatment of type 2 diabetes. UltibroBreezhaler and XoternaBreezhaler received positive opinions from the Committee for the treatment of chronic obstructive pulmonary disease (COPD).

The Committee recommended that Tybost should be granted a marketing authorisation for the treatment of human immunodeficiency virus-1 (HIV-1) infection in combination with protease inhibitors atazanavir and darunavir. The Committee also gave a positive recommendation for the approval of Grastofil, a biosimilar medicine for the treatment of neutropenia.

Negative opinion for Delamanid

The Committee adopted a negative opinion for Delamanid which was intended for the treatment of multi-drug resistant tuberculosis.

Re-examination of two initial recommendations for marketing authorisation

The CHMP adopted a positive re-examination opinion for Defitelio, for the treatment of severe hepatic veno-occlusive disease (VOD) in patients undergoing blood stem-cell transplantation. It also adopted a final negative opinion following the re-examination of Xeljanz which was intended for the treatment of moderate to severe active rheumatoid arthritis.

Investigation on GLP-1 based diabetes therapies concluded

The CHMP has finalised a review of GLP-1 based diabetes therapies. The Committee concluded that available data do not confirm recent concerns over an increased pancreatic cancer risk with these medicines. For more information, please see the press release on the Agency's website.